Carol Sargeant

5.4k total citations · 4 hit papers
17 papers, 4.2k citations indexed

About

Carol Sargeant is a scholar working on Epidemiology, Endocrinology, Diabetes and Metabolism and Hepatology. According to data from OpenAlex, Carol Sargeant has authored 17 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Epidemiology, 8 papers in Endocrinology, Diabetes and Metabolism and 8 papers in Hepatology. Recurrent topics in Carol Sargeant's work include Liver Disease Diagnosis and Treatment (15 papers), Diet, Metabolism, and Disease (8 papers) and Liver Disease and Transplantation (4 papers). Carol Sargeant is often cited by papers focused on Liver Disease Diagnosis and Treatment (15 papers), Diet, Metabolism, and Disease (8 papers) and Liver Disease and Transplantation (4 papers). Carol Sargeant collaborates with scholars based in United States and Belgium. Carol Sargeant's co-authors include Arun J. Sanyal, Melissa J. Contos, Richard K. Sterling, Velimir A. Luketic, Prem Puri, Onpan Cheung, Mitchell L. Shiffman, Faridoddin Mirshahi, Michelle M. Wiest and Richard T. Stravitz and has published in prestigious journals such as Gastroenterology, Hepatology and Journal of Hepatology.

In The Last Decade

Carol Sargeant

17 papers receiving 4.0k citations

Hit Papers

A lipidomic analysis of nonalcoholic fatty liver disease 2003 2026 2010 2018 2007 2003 2009 2009 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A lipidomic analysis of nonalcoholic fatty liver disease
    2007 1.1k citations Prem Puri, Rebecca Baillie et al. Hepatology profile →
  2. Clinical and Histologic Spectrum of Nonalcoholic Fatty Liver Disease Associated With Normal Alt Values
    2003 909 citations Melissa J. Contos, Carol Sargeant et al. Hepatology profile →
  3. The plasma lipidomic signature of nonalcoholic steatohepatitis†‡
    2009 521 citations Prem Puri, Michelle M. Wiest et al. Hepatology profile →
  4. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis #
    2009 478 citations Keith D. Lindor, Kris V. Kowdley et al. Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Carol Sargeant United States 12 3.5k 1.7k 1.5k 851 728 17 4.2k
Aynur Ünalp United States 17 4.1k 1.2× 2.1k 1.3× 1.7k 1.1× 673 0.8× 702 1.0× 32 4.6k
M. Marietti Italy 8 4.0k 1.1× 1.6k 1.0× 1.5k 1.0× 595 0.7× 975 1.3× 17 4.6k
Claire Z. Larter Australia 18 3.1k 0.9× 1.3k 0.8× 937 0.6× 595 0.7× 823 1.1× 24 3.7k
Etsuko Hashimoto Japan 35 4.4k 1.3× 1.8k 1.1× 2.3k 1.5× 771 0.9× 681 0.9× 107 5.2k
Shivakumar Chitturi Australia 25 4.4k 1.3× 2.1k 1.3× 1.5k 1.0× 745 0.9× 766 1.1× 40 5.5k
Romina Lomonaco United States 25 3.6k 1.0× 2.2k 1.4× 1.1k 0.8× 734 0.9× 710 1.0× 37 4.2k
Kanji Yamaguchi Japan 30 2.4k 0.7× 1.2k 0.7× 889 0.6× 508 0.6× 879 1.2× 105 3.5k
Fabio Nascimbeni Italy 28 4.1k 1.2× 2.2k 1.4× 1.5k 1.0× 563 0.7× 594 0.8× 54 4.8k
Mara Brizi Italy 9 3.0k 0.9× 1.8k 1.1× 740 0.5× 550 0.6× 591 0.8× 15 3.7k
Manirath Srishord United States 13 3.6k 1.0× 1.8k 1.1× 1.6k 1.0× 606 0.7× 453 0.6× 28 4.0k

Countries citing papers authored by Carol Sargeant

Since Specialization
Citations

This map shows the geographic impact of Carol Sargeant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carol Sargeant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carol Sargeant more than expected).

Fields of papers citing papers by Carol Sargeant

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carol Sargeant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carol Sargeant. The network helps show where Carol Sargeant may publish in the future.

Co-authorship network of co-authors of Carol Sargeant

This figure shows the co-authorship network connecting the top 25 collaborators of Carol Sargeant. A scholar is included among the top collaborators of Carol Sargeant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carol Sargeant. Carol Sargeant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Mirshahi, Faridoddin, Mohammad Shadab Siddiqui, Sherry Boyett, et al.. (2015). 1008 Decreased Fecal Microbial Metabolite Enterolactone is a Novel Inflammatory and Oxidative Stress Related Biomarker of Alcoholic Liver Disease. Gastroenterology. 148(4). S–1001. 1 indexed citations
2.
Idowu, Michael O., Mohammad Siddiqui, Carolyn Driscoll, et al.. (2015). De novo hepatic steatosis drives atherogenic risk in liver transplantation recipients. Liver Transplantation. 21(11). 1395–1402. 30 indexed citations
3.
Puri, Prem, Carol Sargeant, Leigh White, et al.. (2015). O044 : Distinct fecal and plasma bile acid metabolome of microbial origin characterizes human nonalcoholic fatty liver disease (NAFLD). Journal of Hepatology. 62. S210–S211. 1 indexed citations
4.
Siddiqui, Mohammad, R. Todd Stravitz, Carolyn Driscoll, et al.. (2015). Evolution of serum atherogenic risk in liver transplant recipients: Role of lipoproteins and metabolic and inflammatory markers. Liver Transplantation. 21(5). 623–630. 36 indexed citations
5.
Siddiqui, Mohammad Shadab, Michael Fuchs, Michael O. Idowu, et al.. (2014). Severity of Nonalcoholic Fatty Liver Disease and Progression to Cirrhosis Are Associated With Atherogenic Lipoprotein Profile. Clinical Gastroenterology and Hepatology. 13(5). 1000–1008.e3. 174 indexed citations
6.
Siddiqui, Mohammad, Todd R. Stravitz, Carolyn Driscoll, et al.. (2014). Evolution of Serum Atherogenic Risk in Liver Transplant Recipients: Role of Lipoproteins, Metabolic, and Inflammatory Markers. The American Journal of Gastroenterology. 109. S157–S158. 1 indexed citations
7.
Stewart, Karen, Deborah L. Haller, Carol Sargeant, et al.. (2014). Readiness for behaviour change in non‐alcoholic fatty liver disease: implications for multidisciplinary care models. Liver International. 35(3). 936–943. 51 indexed citations
8.
Siddiqui, Muhammad S., Richard K. Sterling, Velimir A. Luketic, et al.. (2013). Association Between High-Normal Levels of Alanine Aminotransferase and Risk Factors for Atherogenesis. Gastroenterology. 145(6). 1271–1279.e3. 66 indexed citations
9.
Lindor, Keith D., Kris V. Kowdley, Velimir A. Luketic, et al.. (2009). High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis #. Hepatology. 50(3). 808–814. 478 indexed citations breakdown →
10.
Puri, Prem, Michelle M. Wiest, Onpan Cheung, et al.. (2009). The plasma lipidomic signature of nonalcoholic steatohepatitis†‡. Hepatology. 50(6). 1827–1838. 521 indexed citations breakdown →
11.
Puri, Prem, Rebecca Baillie, Michelle M. Wiest, et al.. (2007). A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology. 46(4). 1081–1090. 1056 indexed citations breakdown →
12.
Cheung, Onpan, Ashwani Kapoor, Prem Puri, et al.. (2007). The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. Hepatology. 46(4). 1091–1100. 85 indexed citations
13.
Sanyal, Arun J., Colin Banas, Carol Sargeant, et al.. (2006). Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C†. Hepatology. 43(4). 682–689. 392 indexed citations
14.
Sanyal, Arun J., Melissa J. Contos, Carol Sargeant, et al.. (2004). A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clinical Gastroenterology and Hepatology. 2(12). 1107–1115. 346 indexed citations
15.
16.
Contos, Melissa J., Carol Sargeant, Robert A. Fisher, et al.. (2003). Clinical and Histologic Spectrum of Nonalcoholic Fatty Liver Disease Associated With Normal Alt Values. Hepatology. 37(6). 1286–1292. 909 indexed citations breakdown →
17.
Haller, D.G., et al.. (2003). 733 A behavioral analysis of nonalcoholic fatty liver disease: implications for the clinician. Hepatology. 38. 513–513. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aynur Ünalp Breakdown of academic impact, for papers by M. Marietti Breakdown of academic impact, for papers by Claire Z. Larter Breakdown of academic impact, for papers by Etsuko Hashimoto Breakdown of academic impact, for papers by Shivakumar Chitturi Breakdown of academic impact, for papers by Romina Lomonaco Breakdown of academic impact, for papers by Kanji Yamaguchi Breakdown of academic impact, for papers by Fabio Nascimbeni Breakdown of academic impact, for papers by Mara Brizi Breakdown of academic impact, for papers by Manirath Srishord
Rankless by CCL
2026